Apalutamide
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Apalutamide: Repurposing Evaluation — No Predictions Available
Summary
Apalutamide (DB11901) is a drug currently not approved in Finland. The TxGNN model returned no predicted new indications for this candidate in the current dataset. Critical data items — including original indications, mechanism of action, and safety information — are also absent, making a complete repurposing evaluation impossible at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in current dataset |
| Predicted New Indication | None returned by TxGNN |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A |
| Finland Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Finland Market Information
Apalutamide has no registered authorizations in Finland. No license records, approved dosage forms, or approved indications are available in the current dataset.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model returned no candidate indications for Apalutamide, and the absence of original indication data, mechanism of action, and safety information means there is no basis for a repurposing evaluation at this time.
To proceed, the following is needed:
- TxGNN prediction: Re-run the prediction pipeline with Apalutamide's DrugBank graph embeddings to determine whether a candidate indication score can be generated
- Mechanism of action: Query the DrugBank API (DB11901) to retrieve pharmacological class, target, and MOA
- Original indications: Parse the TFDA package insert PDF (already located per query log) to extract approved indications and safety warnings
- Finland regulatory check: Verify Fimea database directly to confirm current approval and market status
- Safety data: Extract key warnings, contraindications, and drug interactions from the package insert before proceeding to safety screen
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.